Search PubMed⌕ Search

Biomedical subjects

T Nakada

Publications and source records attributed to T Nakada.

At least 73 records · Page 4Linked to original sources
PubMed2000

Dermoid cyst in the adrenal gland.

The first case of a dermoid cyst arising from the unilateral adrenal gland is reported with special reference to its embryonal development and imaging analysis.

Adrenal Gland Neoplasms↗
PubMed1999

Perceptual processing of stereopsis in humans: high-field (3.0-tesla) functional MRI study.

Cortical activation associated with stereopsis was studied in eight right-handed neurosurgeons professionally trained in stereoscopic vision. The activation map associated with viewing three-dimensional images, as contrasted to viewing the corresponding two-dimensional images of identical contents (images of MR angiography), showed consistent activation in the cortex adjacent to the intraparietal sulcus. The study further demonstrated a dominant role of the right hemisphere in perceptual processing of stereopsis in humans.

Adult↗
PubMed1999

Glucocorticoid hormone suppression of human neutrophil-mediated tumor cell cytostasis.

In the present study, we have investigated the effect of glucocorticoid hormones on neutrophil-mediated tumor cell cytostasis and found that hydrocortisone and a synthetic hormone, dexamethasone (Dex), inhibited cytostasis in the presence or absence of tumor necrosis factor-alpha. The effect of Dex was completely reversed by a glucocorticoid receptor antagonist, RU38486. To clarify the underlying mechanisms, we examined effects of Dex on the binding avidity of beta2 integrin on the neutrophil surface and how these might in turn affect neutrophil-to-tumor cell binding. Dex was found to inhibit these neutrophil properties, and RU38486 completely suppressed both forms of Dex inhibition. Taken together, our findings suggest that glucocorticoid hormone inhibition of neutrophil-mediated tumor cell cytostasis is at least partially due to a lowering of the ligand binding avidity of beta2 integrin on the neutrophil surface.

Animals↗
PubMed1999

Microdeletion of the DAZ (deleted in azoospermia) gene or the YRRM (Y chromosome ribonucleic acid recognition motif) gene does not occur in patients with Klinefelter's syndrome with and without spermatogenesis.

OBJECTIVE: To evaluate the occurrence of microdeletions of the Y chromosome involving the DAZ and YRRM genes in patients with Klinefelter's syndrome with and without spermatogenesis. DESIGN: Controlled clinical study. SETTING: Yamagata University Hospital, Yamagata, Japan. PATIENT(S): Patients with Klinefelter's syndrome with spermatogenesis (n = 1) and without spermatogenesis (n = 20) and a control group of men of proven fertility (n = 10). INTERVENTION(S): Blood and semen sampling and testicular biopsy. MAIN OUTCOME MEASURE(S): Semen analysis, polymerase chain reaction amplification of 32 DNA loci on the long arm of the Y chromosome involving the DAZ (deleted in azoospermia) and YRRM (Y chromosome ribonucleic acid recognition motif) genes, and measurement of plasma FSH, LH, and testosterone levels. RESULT(S): No microdeletions of 32 loci were found in any of the patients with Klinefelter's syndrome, either with or without spermatogenesis. Plasma LH and FSH levels were abnormally high and testosterone levels were reduced in all the patients with Klinefelter's syndrome. American Society for Reproductive Medicine.) CONCLUSION(S): Severe impairment of spermatogenesis in patients with Klinefelter's syndrome is not caused by microdeletions of the Y chromosome involving the DAZ and YRRM genes.

DNA↗
PubMed1999

Effects of estrogen and progesterone on urinary bladder in female rabbit: evaluation by quantitative morphometric analysis.

OBJECTIVES: To investigate possible effects of estrogen and/or progesterone on the histologic characteristics of female rabbit urinary bladders, we carried out quantitative morphometric analysis of the rabbit bladders. METHODS: Mature female rabbits were treated by ovariectomy with and without successive estrogen and/or progesterone administration. Area densities of the connective tissue (CT) and smooth muscle (SM) cells, the area of single SM cells, and the thickness of the bladder wall were determined by computer-assisted quantitative morphometric analysis. RESULTS: Six weeks after each treatment, ovariectomy alone resulted in a decrease in CT density of the bladder. Successive estrogen treatment increased the bladder wet weight and SM cell density within the bladder wall. Progesterone treatment reduced CT degradation in ovariectomized rabbits. Sex steroids did not significantly influence the area of each SM cell. There was no significant difference in histologic characteristics between the rabbits treated by estrogen alone and those treated by combination (estrogen and progesterone) therapy. CONCLUSIONS: Ovariectomy and successive hormonal replacement therapy resulted in morphologic changes within the rabbit urinary bladder. Cotreatment with progesterone did not significantly change the morphologic findings produced by estrogen treatment alone.

Animals↗
PubMed1999

Relation between urethral elasticity and bladder outlet obstruction and histologic composition of the prostate in patients with benign prostatic hyperplasia.

OBJECTIVES: In benign prostatic hyperplasia (BPH), bladder outlet obstruction is caused by mechanical blockage resulting from an enlarged prostate, and by the increased tone of prostatic smooth muscle. In patients with obstructive BPH, the prostatic urethra urodynamically corresponds to the flow-controlling zone (FCZ). We sought to investigate the relation between the obstruction and elastic properties of the FCZ and the histologic composition of the prostate in symptomatic patients with BPH. METHODS: The grade of infravesical obstruction was classified according to preoperative pressure-flow data from 30 men with symptomatic BPH, and the elastic properties of the FCZ were evaluated as the mean elastance, which was calculated using the three-parameter model. The area densities of smooth muscle, fibrous tissue, epithelium, and lumen were determined by quantitative morphometry, using BPH tissue obtained by transurethral resection. RESULTS: The area density of smooth muscle had a negative correlation with mean elastance (p = -0.50, P <0.01), the linear passive urethral resistance relation (p = -0.43, P <0.05), and the group-specific urethral resistance factor (p = -0.39, P <0.05). No other histologic element was correlated with these variables. CONCLUSIONS: Our results suggest that urethral elasticity and bladder outlet obstruction grade are influenced by the relative content of smooth muscle within the prostate in patients with BPH.

Aged↗
PubMed1999

Analysis of protooncogene c-erbB-2 in benign and malignant human prostate.

In this report, we characterized the c-erbB-2 gene and its product in prostatic cancer cells. Three prostatic cancer cell lines (PC3, DU145 and TSU-Pr1), one primary prostatic cancer and four benign prostatic hyperplasias (BPH) were studied. In reverse transcribed polymerase chain reaction, c-erbB-2 mRNA was demonstrated in all three cell lines and prostatic cancer tissues as well as BPH. The c-erbB-2 protein was expressed higher in prostatic cancer cells and tissues as compared with benign tissue by enzyme immunoassay, but it was not statistically significant. Immunohistochemical study, with the monoclonal antibody SV2-61gamma that recognizes the extracellular domain of c-erbB-2, showed that all the prostatic tissues and cells had reactivity. Antigenicity was mainly in the cytoplasm. Analysis of genomic DNA failed to disclose gene amplifications or rearrangements of c-erbB-2 in both prostatic cancer and BPH. The sequence of amplified c-erbB-2, which corresponds to transmembrane domain, disclosed wild type in all prostatic cancer cells. These results demonstrate that although the number is limited, c-erbB-2 gene and protein are expressed in prostatic cancers and benign prostates. In the previous studies on c-erbB-2 expression in prostatic tissue, mainly conducted by immunohistochemistry, its frequency varies among each study, ranging from less than 0% to 100%. Therefore, to evaluate the c-erbB-2 in prostatic tissue precisely, it is also necessary to detect mRNA of c-erbB-2 as demonstrated in our study.

Blotting, Southern↗
PubMed1999

Relationship between clear cell/compact cell ratio and computed tomographic attenuation number in adrenocortical adenoma.

Clear cell/compact cell ratio in histologic sections from 21 resected adrenocortical adenomas was assessed. Seven patients had Cushing's syndrome another 7 had primary aldosteronism caused by adrenal adenomas and 7 had non-hyperfunctioning adenomas. The results were correlated with the corresponding unenhanced CT attenuation numbers. There was a negative correlation between clear cell/compact cell ratios and unenhanced CT attenuation numbers. However, CT attenuation numbers did not show significant differences between cortisol-producing, aldosterone-producing and nonfunctioning adenomas. These facts suggest that clear cell/compact cell ratio in adrenocortical adenomas accounts for their attenuation number on unenhanced CT scans. However, it is difficult with the use of unenhanced CT attenuation numbers to differentiate cortisol-producing adenomas from aldosterone-producing and nonhyperfunctioning adenomas.

Adrenal Cortex Neoplasms↗
PubMed1999

Adrenal adenoma with foci of oncocytes in a patient with pre-Cushing's syndrome.

A case of unilateral adrenal adenoma with foci of oncocytes in a 64-year-old woman is reported. The tumour manifested clinically pre-Cushing's syndrome with autonomous steroidogenesis which was insufficient to cause typical features of Cushing's syndrome. Whether the pathogenesis of oncocytes and adenoma cells, which were thought to have some metabolic deficiency in the present tumour, are linked remains to be determined.

Adenoma↗
PubMed1999

In vitro effect of amezinium on the rabbit urinary bladder: muscle strip and whole bladder evaluation.

Dose-response studies for norepinephrine and amezinium were obtained for isolated muscle strips and in vitro whole bladder preparations to investigate the effect of amezinium on the bladder. Specimens (strips from the bladder base and body, and the whole bladder) were obtained from mature female rabbits. By the muscle strip study, amezinium showed a weak contractile effect (up to 40% of spontaneous contraction) on strips from the bladder base. Muscle strips from the bladder body presented no response to amezinium. In the whole bladder preparation, administration of norepinephrine showed an increase in intravesical pressure in 4 out of 7 rabbits, whereas administration of amezinium had negligible effect on intravesical pressure. Administration of amezinium showed no influence on strips from the bladder body and the whole bladder preparation. Direct contractile response in muscle strips from the bladder base by amezinium appeared to be a favourable effect considering urinary storage.

Animals↗
PubMed1999

Comparison of voiding disturbances in patients with LUTS and BPH at home and by episodic checks at an outpatient clinic.

To clarify the presence of voiding disturbances in patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), measurements of the capacity at normal desire to void (CNDV), residual urine volume (RUV) and RUV rate at home and in a hospital were done. It has been found that (1) RUV and RUV rate in patients with BPH were markedly greater than that in the normal group and LUTS patients staying at home. Moreover, there was no difference in RUV and RUV rate between the normal group and the LUTS patients. (2) RUV and RUV rate in patients with LUTS and BPH decreased more markedly without changing CNDV when the patients stayed at home than when they underwent episodic checks in a hospital. In conclusion, frequent checks of LUTS and BPH in patients in their domestic environment can probably be utilized for management or determination of treatment.

Adult↗
PubMed1999

The prognosis of stage A patients treated with the antiandrogen chlormadinone acetate.

To determine the efficacy of the antiandrogen chlormadinone acetate as a treatment option for stage A prostate cancer, a retrospective analysis of 111 patients who received chlormadinone acetate was done. Of 55 stage A1 patients, progression was seen in one patient (1.8%) 8 years after the diagnosis. Six out of 56 stage A2 patients (10.7%) showed disease progression at 1-7 years (mean 68 months) after the diagnosis. Progression rates associated with antiandrogen therapy for stage A1 and stage A2 patients were lower than those without treatment reported in the literature. It could be assumed that antiandrogen treatment with chlormadinone acetate inhibited the progression.

Aged↗